Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $74.46 USD
Change Today -0.50 / -0.67%
Volume 1.4M
As of 8:10 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Ivan P. Gergel M.D.

AgeTotal Calculated CompensationThis person is connected to 46 board members in 4 different organizations across 8 different industries.

See Board Relationships
As of Fiscal Year 2013


Dr. Ivan P. Gergel, M.D., has been the Chief Medical Officer and Senior Vice President of Drug Development at Nektar Therapeutics since May 19, 2014. Dr. Gergel has more than 25 years of pharmaceutical leadership and drug development experience. He served as the Chief Scientific Officer and Executive Vice President of Research & Development at Endo International Plc, Endo Health Solutions Inc. and Endo Pharmaceuticals Solutions Inc. from April 29, 2008 to March 31, 2014, ...

Read Full Background

Corporate Headquarters*

Minerva House
Dublin, Co. Dublin 4


Phone: 353 1 268 2000
Fax: --

Board Members Memberships*

Director and Member of Technology & Product Development Committee


University of Pennsylvania - The Wharton School
Royal Free and University College Medical School

Other Affiliations*

Annual Compensation*

Total Annual Compensation$372,728

Stock Options*

All Other Compensation$2,133
Unexercisable Options600,000
Unexercisable Options Value$2,455,750
Total Value of Options$2,455,750
Total Number of Options650,000

Total Compensation*

Total Annual Cash Compensation$602,361
Total Short Term Compensation$372,728
Other Long Term Compensation$2,133
Total Calculated Compensation$4,213,251
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENDP:US $74.46 USD -0.50


Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENDO INTERNATIONAL PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at